Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: DavesM who wrote (1694)	8/1/2001 8:48:41 PM
From: vestor	Read Replies (1) \| Respond to of 1722

Am hearing has strong pipeline but it will not be accretive until 2002 at the earliest. In could substantially make up for the loss of Prozac. However I do not know what other drugs they have that will lose patent protection soon. On The generic Prozac front, BRL is said to have received orders for 900,000+ vials of the 20 mg capsule for ship on day one. my source says expect a press release tomorrow or def. Fri. Equates to more than 150 mil. Not bad. the chain I monitor ordered 80% 20 mg capsule and 20% the other forms.

To: DavesM who wrote (1694)	8/1/2001 9:47:26 PM
From: darbyred	Respond to of 1722

It would certainly help; however, it is more than the 20 mg prozac that is being "lost." Apparently Dr. Reddy (RDY) has short term exclusive rights to sell the 40mg generic prozac and PRI has rights to sell generic prozac in another dosage. If the generics (including Barr (BRL)) are successful, Lilly will probably lose substantially more than half its prozac revenue within six months. IMHO.